108 related articles for article (PubMed ID: 19188142)
1. Overcoming cancer immune tolerance and escape.
Clifton GT; Peoples GE
Clin Cancer Res; 2009 Feb; 15(3):749-51. PubMed ID: 19188142
[TBL] [Abstract][Full Text] [Related]
2. Adjuvant properties of listeriolysin O protein in a DNA vaccination strategy.
Peng X; Treml J; Paterson Y
Cancer Immunol Immunother; 2007 Jun; 56(6):797-806. PubMed ID: 17102978
[TBL] [Abstract][Full Text] [Related]
3. A novel human Her-2/neu chimeric molecule expressed by Listeria monocytogenes can elicit potent HLA-A2 restricted CD8-positive T cell responses and impact the growth and spread of Her-2/neu-positive breast tumors.
Seavey MM; Pan ZK; Maciag PC; Wallecha A; Rivera S; Paterson Y; Shahabi V
Clin Cancer Res; 2009 Feb; 15(3):924-32. PubMed ID: 19188163
[TBL] [Abstract][Full Text] [Related]
4. Recombinant Listeria vaccines containing PEST sequences are potent immune adjuvants for the tumor-associated antigen human papillomavirus-16 E7.
Sewell DA; Shahabi V; Gunn GR; Pan ZK; Dominiecki ME; Paterson Y
Cancer Res; 2004 Dec; 64(24):8821-5. PubMed ID: 15604239
[TBL] [Abstract][Full Text] [Related]
5. A gold glyco-nanoparticle carrying a Listeriolysin O peptide and formulated with Advax™ delta inulin adjuvant induces robust T-cell protection against listeria infection.
Rodriguez-Del Rio E; Marradi M; Calderon-Gonzalez R; Frande-Cabanes E; Penadés S; Petrovsky N; Alvarez-Dominguez C
Vaccine; 2015 Mar; 33(12):1465-73. PubMed ID: 25659269
[TBL] [Abstract][Full Text] [Related]
6. Listeriolysin O as a strong immunogenic molecule for the development of new anti-tumor vaccines.
Sun R; Liu Y
Hum Vaccin Immunother; 2013 May; 9(5):1058-68. PubMed ID: 23399758
[TBL] [Abstract][Full Text] [Related]
7. Listeria-based vaccines for cancer treatment.
Paterson Y; Maciag PC
Curr Opin Mol Ther; 2005 Oct; 7(5):454-60. PubMed ID: 16248280
[TBL] [Abstract][Full Text] [Related]
8. Developing recombinant and synthetic vaccines for the treatment of melanoma.
Restifo NP; Rosenberg SA
Curr Opin Oncol; 1999 Jan; 11(1):50-7. PubMed ID: 9914879
[TBL] [Abstract][Full Text] [Related]
9. [Anti-HER2 vaccines: The HER2 immunotargeting future?].
Ladjemi MZ; Jacot W; Pèlegrin A; Navarro-Teulon I
Pathol Biol (Paris); 2011 Jun; 59(3):173-82. PubMed ID: 19481373
[TBL] [Abstract][Full Text] [Related]
10. Multiple effector mechanisms induced by recombinant Listeria monocytogenes anticancer immunotherapeutics.
Wallecha A; Carroll KD; Maciag PC; Rivera S; Shahabi V; Paterson Y
Adv Appl Microbiol; 2009; 66():1-27. PubMed ID: 19203646
[TBL] [Abstract][Full Text] [Related]
11. Cancer immunotherapy using Listeria monocytogenes and listerial virulence factors.
Wood LM; Guirnalda PD; Seavey MM; Paterson Y
Immunol Res; 2008; 42(1-3):233-45. PubMed ID: 19018479
[TBL] [Abstract][Full Text] [Related]
12. Adenovirus-based vaccine against Listeria monocytogenes: extending the concept of invariant chain linkage.
Jensen S; Steffensen MA; Jensen BA; Schlüter D; Christensen JP; Thomsen AR
J Immunol; 2013 Oct; 191(8):4152-64. PubMed ID: 24043891
[TBL] [Abstract][Full Text] [Related]
13. Cancer vaccines: an update.
Hipp JD; Hipp JA; Lyday BW; Minev BR
In Vivo; 2000; 14(5):571-85. PubMed ID: 11125541
[TBL] [Abstract][Full Text] [Related]
14. Development of a Listeria monocytogenes based vaccine against prostate cancer.
Shahabi V; Reyes-Reyes M; Wallecha A; Rivera S; Paterson Y; Maciag P
Cancer Immunol Immunother; 2008 Sep; 57(9):1301-13. PubMed ID: 18273616
[TBL] [Abstract][Full Text] [Related]
15. Genetic immunization of mice against Listeria monocytogenes using plasmid DNA encoding listeriolysin O.
Cornell KA; Bouwer HG; Hinrichs DJ; Barry RA
J Immunol; 1999 Jul; 163(1):322-9. PubMed ID: 10384131
[TBL] [Abstract][Full Text] [Related]
16. In the FVB/N HER-2/neu transgenic mouse both peripheral and central tolerance limit the immune response targeting HER-2/neu induced by Listeria monocytogenes-based vaccines.
Singh R; Paterson Y
Cancer Immunol Immunother; 2007 Jun; 56(6):927-38. PubMed ID: 17131121
[TBL] [Abstract][Full Text] [Related]
17. Immune responses of mice to vaccinia virus recombinants expressing either Listeria monocytogenes partial listeriolysin or Brucella abortus ribosomal L7/L12 protein.
Baloglu S; Boyle SM; Vemulapalli R; Sriranganathan N; Schurig GG; Toth TE
Vet Microbiol; 2005 Aug; 109(1-2):11-7. PubMed ID: 15941627
[TBL] [Abstract][Full Text] [Related]
18. Cytolysin-dependent escape of the bacterium from the phagosome is required but not sufficient for induction of the Th1 immune response against Listeria monocytogenes infection: distinct role of Listeriolysin O determined by cytolysin gene replacement.
Hara H; Kawamura I; Nomura T; Tominaga T; Tsuchiya K; Mitsuyama M
Infect Immun; 2007 Aug; 75(8):3791-801. PubMed ID: 17517863
[TBL] [Abstract][Full Text] [Related]
19. Attenuated Listeria monocytogenes, a Mycobacterium tuberculosis ESAT-6 antigen expression and delivery vector for inducing an immune response.
Yin Y; Tian D; Jia Y; Gao Y; Fu H; Niu Z; Sun L; Jiao X
Res Microbiol; 2012; 163(8):540-9. PubMed ID: 22835946
[TBL] [Abstract][Full Text] [Related]
20. A critical role for phospholipase C in protective immunity conferred by listeriolysin O-deficient Listeria monocytogenes.
Orgun NN; Way SS
Microb Pathog; 2008 Feb; 44(2):159-63. PubMed ID: 17888620
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
